

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7928159
<b>Application Number:</b>	10529014
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8835
<b>Title of Invention:</b>	Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities
<b>First Named Inventor/Applicant Name:</b>	Kengo Akimoto
<b>Customer Number:</b>	55694
<b>Filer:</b>	Christopher P. Bruenjes/Tiffany Pender
<b>Filer Authorized By:</b>	Christopher P. Bruenjes
<b>Attorney Docket Number:</b>	47237-0532-00 (216940)
<b>Receipt Date:</b>	30-JUN-2010
<b>Filing Date:</b>	05-MAY-2005
<b>Time Stamp:</b>	15:41:14
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$180
RAM confirmation Number	2456
Deposit Account	500573
Authorized User	GRUDZIECKI, RONALD

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		47237_0532_216940_IDS_and_PTO_Form_1449.pdf	198688 a3b60864a4c1733bc3234d0179ca809a732906f	yes	3
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Transmittal Letter		1		2
	Information Disclosure Statement (IDS) Filed (SB/08)		3		3
<b>Warnings:</b>					
<b>Information:</b>					
2	NPL Documents	47237_0532_216940_JP-Office_Action_dated_June_8_2010.pdf	124084 085144cedf995f09703b45aaf63296ef60f8b2e	no	3
<b>Warnings:</b>					
<b>Information:</b>					
3	Foreign Reference	47237_0532_216940_Reference_JP200_8074.pdf	1863525 ff7220e0b482b11ba47adc024ba9ef6bc45dc943	no	27
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	47237_0532_216940_Reference_JP10_191886.pdf	1663399 c11a812678cc9c02de66269a33279c75a38b6e	no	24
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	47237_0532_216940_Reference_Stroke.pdf	1817457 8d72719a7e0ba180954a341401db22dcd77eaa2	no	15
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	47237_0532_216940_Reference_Science_Daily_Brain_Atrophy.pdf	106278 f005c0bf5db617a71ba011569223142fbaeb00f	no	2
<b>Warnings:</b>					
<b>Information:</b>					

7	NPL Documents	47237_0532_216940_Reference_Evaluation_of_Mental_Retardation.pdf	665153 6db343c3e1351313169bdc3447a5d2dc7bb4860	no	8
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	47237_0532_216940_Reference_The_Merck_Manual.pdf	698950 7dbdb36321c7cbb6b7dc0253c3280281c2e0f6b	no	6
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	47237_0532_216940_Reference_Essential_Fatty_Acids.pdf	1079311 f93831a975a796754694827381e9b24693c29c01c	no	10
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	47237_0532_216940_Reference_Time_to_give_up_on_a_singl_e_explanation.pdf	407527 7d2f801e57545ad6cc4491c141471cbb45e0f	no	3
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	47237_0532_216940_Reference_The_Influence_of_low_intake.pdf	598136 011d247515d78db018dbdbed353812d4dc2b3c75	no	6
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	47237_0532_216940_Reference_Cecil's_Textbook_of_Medicine.pdf	488955 0ad23524d451d7d207d5b166b6952aa53b44c2	no	5
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	47237_0532_216940_Reference_The_Contribution_of_Risk_Factors.pdf	687338 6954e8751c217c7abecf183c8d07993bb55d45	no	4
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	47237_0532_216940_Reference_Cerebral_Arteriosclerosis.pdf	65126 52ac3dd19b0fc23769239986ca73980ac7bb396	no	2
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	47237_0532_216940_Reference_Vance.pdf	148558 dca05dab3c2bba0848155b4d292a2c5e7d7a0bb7	no	2
<b>Warnings:</b>					
<b>Information:</b>					

16	NPL Documents	47237_0532_216940_Reference_Fragile_X_Syndrome.pdf	641572 3ad2aed20029b6a040b071514c1d6c38164c0e	no	5
<b>Warnings:</b>					
<b>Information:</b>					
17	Fee Worksheet (PTO-875)	fee-info.pdf	30684 2c138b8c884c6e99d7a040b613e13e6aa41001c	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total File Size (in bytes):</b>			11284741		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					